Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Linh Nguyen-Phuong

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
JCO Clinical Cancer Informatics|February 28, 2025
Computational Modeling for Circulating Cell-Free DNA in Clinical OncologyLinh Nguyen Phuong, Sébastien Salas, Sébastien Benzekry
Neuropharmacology|April 27, 2025
Structural insights into the function, dysfunction and modulation of Kv3 channelsManuel Covarrubias, Qiansheng Liang, Linh Nguyen-Phuong, et al.
International Journal of Environmental Research and Public Health|March 7, 2020
Perceptions of Dentists and Non-Professionals on Some Dental Factors Affecting Smile Aesthetics: A Study from VietnamVo Truong Nhu Ngoc, Dang-Khoa Tran, Truong Manh Dung, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2025
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapyCaroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, et al.
Scientific Reports|November 25, 2025
Prevalence and factors associated with metabolic syndrome and its components among overweight and obese reproductive-age women in Bac Giang, VietnamTuyet Thi Anh Doan, Tu Song Nguyen, Van Khanh Tran, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
JCO Clinical Cancer Informatics|February 28, 2025
Computational Modeling for Circulating Cell-Free DNA in Clinical OncologyLinh Nguyen Phuong, Sébastien Salas, Sébastien Benzekry
Neuropharmacology|April 27, 2025
Structural insights into the function, dysfunction and modulation of Kv3 channelsManuel Covarrubias, Qiansheng Liang, Linh Nguyen-Phuong, et al.
International Journal of Environmental Research and Public Health|March 7, 2020
Perceptions of Dentists and Non-Professionals on Some Dental Factors Affecting Smile Aesthetics: A Study from VietnamVo Truong Nhu Ngoc, Dang-Khoa Tran, Truong Manh Dung, et al.
European Journal of Cancer (Oxford, England : 1990)|November 23, 2025
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapyCaroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, et al.
Scientific Reports|November 25, 2025
Prevalence and factors associated with metabolic syndrome and its components among overweight and obese reproductive-age women in Bac Giang, VietnamTuyet Thi Anh Doan, Tu Song Nguyen, Van Khanh Tran, et al.
Nature Cancer|June 21, 2022
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancerAya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, et al.
Cancer Discovery|December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance MutationsAlexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery|September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound MutationsJessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Pageof 1